Duhn Therapeutics SAS, a clinical-stage company co-founded by Landmark BioVentures AG, and OM Pharma SA, a Swiss based global biopharmaceutical company. We are mission-driven to bring new solutions to cancer patients by reshaping the immunological profile of their tumors.

The lead program, DHN198, is a clinical-stage asset for solid cancers associated with or resulting from chronic non-resolved immunosuppressive inflammation.

Building upon years of collaboration with translational researchers and clinicians from the University of Bourgogne and the Georges François Leclerc Cancer Treatment Center (CGFL), Duhn Therapeutics is strategically located in Dijon, France, where it plans to conduct its in-house R&D operations in partnership with the Laboratory of Immunology and Cancer Immunotherapy (LIIC). 
Duhn Therapeutics is a company of the nexus of Landmark BioVentures (www.landmarkbioventures.com)


Duhn Therapeutics

Org chart

Teams

Offices